The Impact of \u3ci\u3emsaABCR\u3c/i\u3e On \u3ci\u3esarA\u3c/i\u3e-Associated Phenotypes is Different in Divergent Clinical Isolates of \u3ci\u3eStaphylococcus aureus\u3c/i\u3e by Rom, Joseph S. et al.
The University of Southern Mississippi 
The Aquila Digital Community 
Faculty Publications 
11-18-2019 
The Impact of msaABCR On sarA-Associated Phenotypes is 
Different in Divergent Clinical Isolates of Staphylococcus aureus 
Joseph S. Rom 
University of Arkansas for Medical Sciences 
Aura M. Ramirez 
University of Arkansas for Medical Sciences 
Karen E. Beenken 
University of Arkansas for Medical Sciences 
Gyan S. Sahukhal 
University of Southern Mississippi 
Mohamed O. Elasri 
University of Southern Mississippi, Mohamed.Elasri@usm.edu 
See next page for additional authors 
Follow this and additional works at: https://aquila.usm.edu/fac_pubs 
 Part of the Immunology and Infectious Disease Commons 
Recommended Citation 
Rom, J. S., Ramirez, A. M., Beenken, K. E., Sahukhal, G. S., Elasri, M. O., Smeltzer, M. S. (2019). The Impact 
of msaABCR On sarA-Associated Phenotypes is Different in Divergent Clinical Isolates of Staphylococcus 
aureus. Infection and Immunity. 
Available at: https://aquila.usm.edu/fac_pubs/16827 
This Article is brought to you for free and open access by The Aquila Digital Community. It has been accepted for 
inclusion in Faculty Publications by an authorized administrator of The Aquila Digital Community. For more 
information, please contact Joshua.Cromwell@usm.edu. 
Authors 
Joseph S. Rom, Aura M. Ramirez, Karen E. Beenken, Gyan S. Sahukhal, Mohamed O. Elasri, and Mark S. 
Smeltzer 








The impact of msaABCR on sarA-associated phenotypes is different in divergent 6 
clinical isolates of Staphylococcus aureus 7 
 8 
Joseph S. Roma, Aura M. Ramireza, Karen E. Beenkena, Gyan S. Sahukhalc, Mohamed O. 9 
Elasric, and Mark S. Smeltzera,b# 10 
 11 
 12 
aDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, 13 
Little Rock, AR  72205 14 
 15 
bDepartment of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, 16 
AR  72205 17 
 18 
cCenter for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, 19 













#Corresponding author:  Dr. Mark S. Smeltzer 33 
Department of Microbiology and Immunology 34 
University of Arkansas for Medical Sciences 35 
4301 W. Markham 36 
501-686-7958 37 
smeltzermarks@uams.edu  38 
IAI Accepted Manuscript Posted Online 18 November 2019
Infect. Immun. doi:10.1128/IAI.00530-19
Copyright © 2019 Rom et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.










The staphylococcal accessory regulator (sarA) plays an important role in Staphylococcus 40 
aureus infections including osteomyelitis, and the msaABCR operon has been implicated as an 41 
important factor in modulating expression of sarA. Thus, we investigated the contribution of 42 
msaABCR to sarA-associated phenotypes in the S. aureus clinical isolates LAC and UAMS-1. 43 
Mutation of msaABCR resulted in reduced production of SarA and a reduced capacity to form a 44 
biofilm in both strains. Biofilm formation was enhanced in a LAC msa mutant by restoring the 45 
production of SarA, but this was not true in a UAMS-1 msa mutant. Similarly, extracellular 46 
protease production was increased in a LAC msa mutant but not a UAMS-1 msa mutant. This 47 
difference was reflected in the accumulation and distribution of secreted virulence factors and in 48 
the impact of extracellular proteases on biofilm formation in a LAC msa mutant. Most 49 
importantly, it was reflected in the relative impact of mutating msa as assessed in a murine 50 
osteomyelitis model, which had a significant impact in LAC but not in UAMS-1. In contrast, 51 
mutation of sarA had a greater impact on all of these in vitro and in vivo phenotypes by 52 
comparison to mutation of msaABCR, and it did so in both LAC and UAMS-1. These results 53 
suggest that, at least in osteomyelitis, it would be therapeutically preferable to target sarA rather 54 
than msaABCR to achieve the desired clinical result, particularly in the context of divergent 55 
clinical isolates of S. aureus.  56 










Mutation of the staphylococcal accessory regulator (sarA) attenuates the virulence of 58 
divergent clinical isolates of Staphylococcus aureus in animal models of bacteremia, post-59 
surgical osteomyelitis, and infective endocarditis (1-3). It also limits biofilm formation in vitro and 60 
in vivo to a degree that can be correlated with increased antibiotic susceptibility (2, 4-6). The 61 
effector molecule of the sarA regulatory system is a 15 kDa protein that has been shown to 62 
impact the production of multiple S. aureus virulence factors at a transcriptional level and by 63 
modulating the stability of mRNA (7-12). We have also demonstrated that an important factor 64 
contributing to the reduced virulence of sarA mutants, and their reduced capacity to form a 65 
biofilm, is the increased production of extracellular proteases and resulting decrease in the 66 
accumulation of multiple S. aureus proteins including both surface-associated and extracellular 67 
virulence factors (1, 13-17).  68 
Thus, the sarA regulatory locus impacts both the production and the accumulation of S. 69 
aureus virulence factors, and this collectively makes an important contribution to diverse 70 
phenotypes that contribute to pathogenesis. This makes sarA a potential therapeutic target, and 71 
efforts have been made to exploit sarA in this regard (17-19). However, S. aureus regulatory 72 
circuits are complex and highly interactive (20), and mutation of other S. aureus regulatory loci 73 
within this circuit has also been shown to increase protease production to a degree that limits 74 
biofilm formation (21-25).  75 
Among these other loci is msa (modulator of sarA), mutation of which was originally 76 
reported to limit the expression of sarA and the production of SarA itself (26). The msa gene 77 
was identified in the 8325-4 strain RN6390 by a transposon insertion in the open-reading frame 78 
SA1233 as designated in the N315 genome, but it was subsequently shown to be part of a four-79 
gene operon now designated msaABCR (27). Genes within the msa operon encode a putative 80 
protein (MsaA) with no known function, a DNA binding protein (MsaB) shown to act as a 81 
transcription factor that regulates expression of numerous genes, and genes encoding a 82 









regulatory RNA (msaC) and an antisense RNA (msaR) complementary to msaB (27). As would 83 
be expected based on the phenotypes of sarA mutants (3, 4, 13, 15, 16, 28) and the role of 84 
msaABCR in enhancing expression of sarA, mutation of msaABCR (hereinafter referred to as 85 
msa) has been correlated with increased protease production and a decreased capacity to form 86 
a biofilm (25, 27, 29).  87 
Mutation of msa was also reported to result in decreased expression of the accessory gene 88 
regulator (agr) in the 8325-4 strain RN6390 but to have the opposite effect in the clinical isolate 89 
UAMS-1 (26). Expression levels of the well-characterized agr-regulated genes encoding alpha 90 
toxin (hla) and protein A (spa) also differed between these two strains, while expression of the 91 
genes encoding aureolysin (aur) and SspA (sspA) were increased in both strains. Differences 92 
between these two strains have also been observed in the phenotype of their isogenic sarA 93 
mutants (30-31). Such reports are not surprising given that RN6390 has a mutation in rsbU that 94 
impacts the sigB regulatory pathway (32), which has also been shown to impact expression of 95 
both agr and sarA as well as protease production (33-34). However, significant differences also 96 
exist among clinical isolates, and to date, such strain-dependent differences have not been 97 
adequately investigated. Thus, the overall impact of msa in divergent clinical isolates, and the 98 
extent to which it is dependent on its interaction with sarA, remains unclear. In this report, we 99 
addressed these issues by generating msa, sarA, and msa/sarA mutants in the methicillin-100 
resistant USA300 strain LAC and the methicillin-sensitive USA200 strain UAMS-1, and 101 
assessed the impact these mutations had on well-defined phenotypes associated with their 102 
isogenic sarA mutants. 103 
RESULTS AND DISCUSSION 104 
Impact of msa on sarA expression. Using an anti-SarA antibody (35), we first assessed 105 
the production of SarA in msa mutants generated in LAC and UAMS-1 by western blot. 106 
Experiments were done using whole cell lysates prepared from equal numbers of CFU 107 
harvested from cultures in the mid-, late-, and post-exponential growth phases. The results were 108 









comparable in both strains (Fig. 1) and confirmed that mutation of msa results in reduced 109 
production of SarA, particularly during the mid- and late-exponential growth phases. However, 110 
while the differences in the abundance of SarA were in most cases statistically significant, they 111 
were also modest in that the amount of SarA present in lysates prepared from LAC and UAMS-112 
1 msa mutants was consistently >50% of that observed in the isogenic parent strain irrespective 113 
of growth stage. This is consistent with transcriptional analysis, which demonstrated that 114 
mutation of msa results in a modest but statistically significant decrease in the level of sarA 115 
transcript in both LAC and UAMS-1 by comparison to the isogenic parent strain (Table 1). 116 
These studies also confirmed that this transcriptional phenotype could be genetically 117 
complemented. These results are consistent with the hypothesis that msa functions upstream to 118 
modulate the expression of SarA. 119 
Impact of msa on biofilm formation. Thus, the important question becomes whether the 120 
reduction in the amount of SarA observed in msa mutants is phenotypically relevant. One of the 121 
primary phenotypes that defines sarA mutants in divergent clinical isolates, including LAC and 122 
UAMS-1, is the reduced capacity to form a biofilm (36). Using a well-established microtiter plate 123 
assay (28), we confirmed that mutation of msa limits biofilm formation in both LAC and UAMS-1, 124 
but to a limited extent by comparison to the isogenic sarA mutants (Fig. 2). The relative impact 125 
of mutating msa vs. sarA was confirmed by demonstrating that concomitant mutation of both 126 
msa and sarA limited biofilm formation to a level comparable to that observed in the isogenic 127 
sarA mutant and well below that observed in the corresponding msa mutant (Suppl. Fig. 1). 128 
These results are also consistent with the hypothesis that msa is upstream of SarA and the 129 
observation that mutation of msa had only a modest impact on the accumulation of SarA, but 130 
they also suggest that the reduced amount of SarA observed in msa mutants is phenotypically 131 
relevant in the context of biofilm formation.  132 
If this is true, then restoring the production of SarA in an msa mutant should restore biofilm 133 
formation. To investigate this, we introduced the same plasmid (pSARA) used to genetically 134 









complement the sarA mutation into an msa mutant. Western blot analysis confirmed that the 135 
accumulation of SarA was restored in both LAC and UAMS-1 msa mutants (Fig. 3). Introducing 136 
pSARA also restored biofilm formation in a LAC msa mutant but not in a UAMS-1 msa mutant 137 
(Fig. 2). The reasons for this strain-dependent difference are unclear, but these results suggest 138 
that msa limits biofilm formation in UAMS-1 owing to a sarA-independent regulatory effect. 139 
Impact of msa on protease production. To investigate the mechanistic basis for these 140 
biofilm phenotypes, we examined the relative impact of mutating sarA and msa on the 141 
production of extracellular proteases. This was based on our previous demonstration that the 142 
increased production of extracellular proteases plays a key role in defining the biofilm-deficient 143 
phenotype of S. aureus sarA mutants (1). In LAC, mutation of msa resulted in a statistically 144 
significant increase in overall protease activity as assessed using both casein- and gelatin-145 
based FRET assays, although the impact was more evident in the casein-based assay than the 146 
gelatin-based assay (Fig. 4). This was not true in a LAC sarA mutant, where the impact of 147 
mutating sarA on protease production was readily evident in both assays (Fig. 4). Additionally, 148 
restoring SarA production in a LAC msa mutant decreased protease production, in the case of 149 
the casein-based assay to wild-type levels. As might be expected based on the relative 150 
sensitivity of the two assays, this was most evident when assessed using the casein-based 151 
assay. However, mutation of msa in UAMS-1 did not have a significant impact on overall 152 
protease activity as assessed using either casein- or gelatin-based FRET assays (Fig. 4). As in 153 
LAC, mutation of sarA in UAMS-1 resulted in a statistically-significant increase in protease 154 
production in both protease assays. These results are also consistent with the hypothesis that 155 
the impact of mutating msa on biofilm formation in UAMS-1 occurs via a sarA-independent 156 
regulatory effect. 157 
This strain-dependent difference was also apparent in assays employing gfp transcriptional 158 
reporter constructs generated with the promoters from each of the genes and/or operons 159 
encoding S. aureus extracellular proteases (aur, splA-F, sspABC and scpAB). Specifically, 160 









expression levels from all four reporters were significantly increased in a LAC msa mutant, but 161 
not to the level observed in the isogenic sarA mutant (Fig. 5). In contrast, fluorescence was not 162 
increased to a significant extent in a UAMS-1 msa mutant with any reporter other than the 163 
scp::gfp, and even then, the increase was modest by comparison to fluorescence levels 164 
observed with the same reporter in the LAC msa mutant and with all four reporters in the 165 
UAMS-1 sarA mutant (Fig. 5). These results suggest that the strain-dependent impact of msa on 166 
protease production is mediated at a transcriptional level.  167 
These results also suggest the possibility of a cause-and-effect relationship between 168 
increased protease production and decreased biofilm formation in a LAC msa mutant. Indeed, 169 
there was an inverse and proportional relationship between protease production and biofilm 170 
formation in LAC and its isogenic sarA, msa, and sarA/msa mutants (Suppl. Fig. 2). However, 171 
this inverse relationship was not apparent in a UAMS-1 msa mutant. Mutation of msa in LAC 172 
also resulted in the decreased accumulation of both Hla and extracellular protein A (eSpa) (Fig. 173 
6). In contrast, in UAMS-1, which does not produce Hla, the accumulation of eSpa was greatly 174 
reduced in a sarA mutant, but not in the isogenic msa mutant. The reduced accumulation of 175 
eSpa observed in a LAC msa mutant was reversed by eliminating the production of extracellular 176 
proteases, while in a UAMS-1 msa mutant, the abundance of eSpa was not affected by the 177 
inability to produce these proteases (Fig. 6).  178 
These results demonstrate that mutating msa results in a significant increase in protease 179 
production in LAC but not in UAMS-1. SDS-PAGE analysis of conditioned medium (CM) from 180 
overnight cultures confirmed the decreased accumulation of high molecular weight (HMW) 181 
proteins in a LAC msa mutant, and that this was reversed by eliminating the production of 182 
extracellular proteases (Fig. 7). As would be expected based on the results discussed above, 183 
this effect was not apparent in a UAMS-1 msa mutant. In contrast, mutation of sarA limited the 184 
accumulation of HMW proteins in CM in both LAC and UAMS-1, and in both cases this was 185 
reversed by eliminating the ability of these mutants to produce extracellular proteases (Fig. 7). 186 









Impact of msa on PIA production. To examine other possibilities, we assessed the 187 
production of the polysaccharide intracellular adhesion (PIA) in msa and sarA mutants. PIA is 188 
known to contribute to biofilm formation, and it has been suggested that it plays a particularly 189 
important role in methicillin-sensitive strains like UAMS-1 (37). However, we were unable to 190 
detect PIA above background levels in LAC, UAMS-1, or their isogenic sarA and msa mutants 191 
(Suppl. Fig. 3). 192 
Impact of msa on extracellular nuclease. Extracellular DNA and the production of 193 
extracellular nucleases have also been implicated in biofilm formation in both methicillin-194 
resistant and methicillin-sensitive strains (38). S. aureus produces at least two nucleases, one 195 
of which (Nuc1) is a secreted extracellular protein while the other (Nuc2) remains bound to the 196 
cell surface (39). Mutation of sarA in UAMS-1 has been shown to result in the increased 197 
production of these nucleases, and at least under in vitro conditions, this has been shown to 198 
limit biofilm formation (40). Based on this, we examined the impact of mutating msa on nuclease 199 
production with a specific focus on the Nuc1 extracellular nuclease. This was facilitated by the 200 
availability of an anti-Nuc1 antibody (16), which allowed us to investigate this issue using 201 
western blots of CM harvested from overnight cultures of each strain. It is important to recognize 202 
that Nuc1 is produced in two forms, the smaller of which (NucA) is proteolytically derived from 203 
the larger (NucB), and both of which are enzymatically active (41).  204 
Relative to the parent strain, Nuc1 was present in increased amounts in a UAMS-1 sarA 205 
mutant, and all of the Nuc1 present that could be detected by western blot was present in the 206 
smaller NucA form (Fig. 8). This suggests that the increased production of extracellular 207 
proteases in a UAMS-1 sarA mutant can be correlated with the absence of NucB. This was 208 
confirmed in western blots with CM from a sarA mutant unable to produce these proteases, in 209 
which case all of the Nuc1 detected was in the NucB form. Moreover, the overall abundance of 210 
Nuc1 was increased in the protease-deficient UAMS-1 sarA mutant by comparison to the sarA 211 
mutant (Fig. 8). The abundance of Nuc1 was also increased in a UAMS-1 msa mutant, and in 212 









this case both NucA and NucB were detectable by western blot. While the overall amount of 213 
Nuc1 was not increased in a protease-deficient UAMS-1 msa mutant, all of the Nuc1 present 214 
was in the larger NucB form. This could be interpreted to suggest that mutation of msa does 215 
result in an increase in protease production in UAMS-1 that is phenotypically apparent, but we 216 
believe this would be an over-interpretation in that, unlike the isogenic protease-deficient sarA 217 
mutant, the amount of Nuc1 did not increase appreciably in the UAMS-1 protease-deficient msa 218 
mutant (Fig. 8). 219 
The increased abundance of Nuc1 observed in a UAMS-1 sarA mutant was not apparent in 220 
a LAC sarA mutant, but it was apparent in the isogenic msa mutant (Fig. 8). Unlike the UAMS-1 221 
msa mutant, all of the Nuc1 detectable by western blot in the LAC msa mutant was present in 222 
the smaller NucA form. This is consistent with the observation that mutating msa had a 223 
significant impact on protease production in LAC but not in UAMS-1. As with the UAMS-1 224 
protease-deficient sarA and msa mutants, only NucB could be detected in CM from the 225 
protease-deficient LAC sarA and msa mutants (Fig. 8). As with a UAMS-1 msa mutant, 226 
eliminating protease production in a LAC msa mutant limited proteolytic processing of Nuc1, but 227 
did not appreciably alter the overall amount. In contrast, the abundance of NucB was also 228 
enhanced in a protease-deficient LAC sarA mutant by comparison to the isogenic sarA mutant 229 
itself. These results demonstrate that the production of Nuc1 is increased in LAC and UAMS-1 230 
sarA and msa mutants. They also indicate that the abundance of Nuc1 is limited by increased 231 
protease production in sarA mutants generated in both strains, but that this is not the case even 232 
in a LAC msa mutants. However, the impact of msa on protease production was still evident in a 233 
LAC msa mutant in that all of the Nuc1 present was present in the smaller NucA form (Fig. 8). 234 
Impact of protease and nuclease production on biofilm formation. Given these 235 
overlapping protease and nuclease phenotypes, we directly examined the impact of eliminating 236 
the production of extracellular proteases or Nuc1 on the biofilm-deficient phenotype of LAC and 237 
UAMS-1 sarA and msa mutants. In both strains, eliminating the ability to produce extracellular 238 









proteases enhanced biofilm formation in both sarA and msa mutants to levels comparable to 239 
those observed in the isogenic parent strain (Fig. 9). This could be interpreted to suggest that 240 
the increased production of extracellular proteases limits biofilm formation in msa mutants, even 241 
in UAMS-1. However, it is important to note that eliminating protease production also enhanced 242 
biofilm formation in UAMS-1 itself to a greater extent than in LAC (Fig. 9). In fact, the increase in 243 
biofilm formation observed in a protease-deficient derivative of UAMS-1 was comparable to that 244 
observed in the UAMS-1 msa mutant, and this was not the case in the same derivatives of LAC. 245 
Thus, we believe these results are also consistent with the conclusion that the increased 246 
production of extracellular protease production limits biofilm formation in a LAC msa mutant but 247 
not in a UAMS-1 msa mutant. 248 
Biofilm formation was also enhanced in LAC and UAMS-1 msa mutants unable to produce 249 
Nuc1, but once again, these results must be interpreted with caution because eliminating the 250 
production of Nuc1 also enhanced biofilm formation in the LAC and UAMS-1 parent strains (Fig. 251 
9). As with protease production, the increase in biofilm formation observed in the nuclease-252 
deficient UAMS-1 msa mutant was less than that observed in the nuclease-deficient LAC msa 253 
mutant, and this was reflected in the relative impact of eliminating Nuc1 production on biofilm 254 
formation (Fig. 9). In contrast, eliminating the production of Nuc1 did have a significant impact 255 
on biofilm formation in a UAMS-1 sarA mutant, but not in a LAC sarA mutant (Fig. 9). This is 256 
consistent with the observation that mutation of msa resulted in an increase in the abundance of 257 
Nuc1 in a UAMS-1 sarA mutant but not in a LAC sarA mutant, although as previously discussed 258 
protease production was shown to limit the abundance and processing of Nuc1 in sarA mutants 259 
generated in both strains. 260 
Impact of msa on staphyloxanthin production. All of the results discussed above are 261 
consistent with a model in which msa functions upstream to enhance the production of SarA, 262 
but also demonstrate that the impact of mutating msa on sarA-associated phenotypes is strain 263 
dependent. There are also reports that mutation of msa in LAC has also been implicated in 264 









phenotypes that have not been previously associated with sarA. One of these is that mutation of 265 
msa in LAC has been reported to result in the reduced production of staphyloxanthin (27), which 266 
has been implicated as an important virulence factor in S. aureus (42). We examined this in 267 
LAC and UAMS-1 sarA and msa mutants, and the results confirmed that mutation of msa in 268 
LAC results in a statistically significant reduction in the production of staphyloxanthin (Fig. 10) 269 
and consequently reduced pigmentation of colonies on agar plates (data not shown). 270 
Importantly, unlike the relative impact of mutating sarA and msa on biofilm formation and 271 
protease production, the impact of mutating msa exceeded that of mutating sarA in this regard, 272 
thus suggesting that the impact of mutating msa on staphyloxanthin production is primarily 273 
independent of its impact on sarA. In UAMS-1 the results of these assays provided an even 274 
more striking contrast. Specifically, staphyloxanthin production was increased in a UAMS-1 sarA 275 
mutant but decreased in the isogenic msa mutant (Fig. 10). Although the decrease observed in 276 
a UAMS-1 msa mutant was not statistically significant, this contrast nevertheless makes it 277 
evident that the impact of mutating msa on staphyloxanthin production in UAMS-1 is 278 
independent of its impact on sarA.  279 
Impact of msa in osteomyelitis. The results discussed above provide insight into the 280 
impact of msa on sarA-associated phenotypes in divergent clinical isolates of S. aureus. 281 
However, they also suggest, specifically with respect to our staphyloxanthin assays, that msa 282 
serves regulatory functions that are independent of its impact on sarA. Moreover, all of these 283 
results are based on in vitro assays that do not necessarily reflect the unique microenvironment 284 
of the bone. Thus, we wanted to directly assess the relative contribution of msa and sarA to 285 
virulence in our murine osteomyelitis model (3, 43). As previously reported (3), mutation of sarA 286 
limited virulence in both strains as assessed based on reactive bone formation and cortical bone 287 
destruction, although in this experiment the reduction in cortical bone destruction observed with 288 
the UAMS-1 sarA mutant did not reach statistical significance (Fig. 11). By comparison, 289 
mutation of msa had only a modest impact on virulence in LAC, particularly in the context of 290 









cortical bone destruction, and it had no significant impact in UAMS-1 in either reactive bone 291 
formation or cortical bone destruction. 292 
CONCLUSIONS 293 
Most reports describing the impact of S. aureus regulatory loci on clinically relevant 294 
phenotypes, including virulence, are based on examination of single loci in a single strain, and 295 
this makes it difficult to reach conclusions regarding the relative potential of different regulatory 296 
loci as therapeutic targets. We have attempted to address this by directly comparing different 297 
regulatory mutants generated in divergent clinical isolates of S. aureus using both in vitro and in 298 
vivo assays (3, 4, 44). The results of these studies have led us to focus on sarA and to 299 
hypothesize that a primary factor contributing to the impact of mutating sarA on virulence and 300 
virulence-associated phenotypes is the increased production of extracellular proteases and the 301 
limitation this imposes on the accumulation of both surface-associated and extracellular 302 
virulence factors (1,16). To date, we have not included the msaABCR operon in these studies, 303 
and it is important to do so given that msa has been shown to function upstream of sarA and to 304 
impact sarA-associated phenotypes including biofilm formation and protease production (25-27, 305 
29). This raises the possibility that msa could also be a viable therapeutic target. Experimentally 306 
addressing this possibility was the focus of the experiments we report. However, the results we 307 
report lead us to conclude that this is not the case for two reasons. First, even in the genetically 308 
and phenotypically divergent clinical isolates LAC and UAMS-1, the impact of mutating msa on 309 
biofilm formation and virulence in our osteomyelitis model is limited by comparison to that of 310 
mutating sarA. Second, the relative impact of mutating msa differed between these two strains 311 
with respect to both of these phenotypes. This emphasizes the need for direct comparative 312 
studies like those we report, particularly given the complexity of S. aureus regulatory circuits 313 
and the diversity among S. aureus strains as represented by the USA300 isolate LAC and the 314 
USA200 strain UAMS-1.  315 
MATERIALS AND METHODS 316 









Bacterial strains and growth conditions. The strains used in these experiments are 317 
summarized in Tables 1 and 2. LAC and UAMS-1 mutants produced during the course of this 318 
work were generated by Φ11-mediated transduction from existing mutants (1, 4, 13, 15, 27, 34, 319 
44-53). Protease reporter plasmids were also introduced into the designated mutants by Φ11-320 
mediated transduction (23). All strains were maintained at −80°C in tryptic soy broth (TSB) 321 
containing 25% (v/v) glycerol. For each experiment, strains under study were retrieved from cold 322 
storage by plating on tryptic soy agar (TSA) with appropriate antibiotic selection. Antibiotics 323 
were incorporated into the culture media as appropriate at the following concentrations: 324 
chloramphenicol, 10 μg ml-1; kanamycin, 50 μg ml-1; and neomycin, 50 μg ml-1; erythromycin, 10 325 
μg ml-1; spectinomycin, 1 mg ml-1; or tetracycline 5 μg ml-1. Kanamycin and neomycin were 326 
always used together to avoid selection of spontaneously resistant strains.  327 
Preparation of S. aureus conditioned media. To prepare conditioned medium (CM), 328 
cultures of each strain were grown overnight (16 hr) in TSB at 37oC with constant shaking. The 329 
optical density at 560 nm (OD560) of each culture was determined and fresh TSB added to 330 
standardize each culture to an equivalent optical density. Cells were then removed by 331 
centrifugation and CM prepared by filter-sterilization. Samples were stored at -80oC until used. 332 
Preparation of whole-cell lysates. Whole cell lysates were prepared as previously 333 
described with minor modification (45). Briefly, strains were cultured at 37oC in TSB with 334 
constant shaking and a medium-to-flask ratio of 0.5. Bacterial cells from a volume of each 335 
culture calculated to obtain an equivalent number of cells were harvested by centrifugation at an 336 
OD560 of approximately 1.5, 4.0, and 10.0, which correspond to the mid‐exponential, late‐337 
exponential, and post‐exponential growth phases, respectively. Cells were washed with sterile 338 
phosphate-buffered saline (PBS) and re-suspended in 750 μl of TEG buffer (25 mM Tris‐HCl, 339 
pH 8.0, 25 mM EGTA). Cell suspensions were stored at -20oC until all samples had been 340 
collected, at which point samples were thawed on ice, transferred to Fastprep Lysing Matrix B 341 
tubes, and lysed in a FastPrep®-24 benchtop homogenizer (MP Biomedicals) using two 40 sec 342 









intervals at a rate of 6.0 m/sec interrupted by a 5 min interval in which the homogenates were 343 
chilled on ice. After centrifugation at 15,000 x g for 10 min at 4oC, supernatants were harvested 344 
and stored at -80oC. 345 
Western blotting. SarA western blots were done with an anti-SarA antibody and 346 
appropriate secondary antibodies as previously described (1, 15, 16). Western blots included at 347 
least two biological replicates. Densitometric values were obtained with a Bio-Rad 348 
ChemiDocMP Imaging System and Image Lab Software (Bio-Rad Laboratories). 349 
RNA isolation and real-time qPCR. Overnight cultures of S. aureus were diluted 1:10 350 
times in fresh TSB and incubated at 37°C with shaking (200 rpm) for 2 hr. The cells were then 351 
normalized to an OD600 of 0.05 in 25 ml TSB in 125 ml conical flask and incubated at 37°C with 352 
shaking (200 rpm). The cells were collected at mid-exponential growth phase. Total RNA was 353 
isolated from cells using a Qiagen RNeasy Maxi column (Qiagen), as previously described (27). 354 
The quality of total RNA was determined by Nanodrop spectrometer readings and 1 μg RNA 355 
was used to synthesize cDNA using iScript™ Reverse Transcription Supermix for RT-qPCR 356 
(Biorad). RT-qPCR was done using iTaq™ Universal SYBR® Green Supermix (Biorad) as 357 
described previously (27). The constitutively expressed gyrase A (gyrA) gene was used as an 358 
endogenous control gene and was included in all experiments. The following primer sequences 359 
were used to measure sarA expression: RT-sarA-F TTTGCTTCAGTGATTCGTTTATTTACTC 360 
and RT-sarA-R GTAATGAGCATGATGAAAGAACTGTATT. Analysis of expression of each 361 
gene was done based on at least three biological replicates. 362 
Static in vitro biofilm assay. Biofilm formation was assessed in vitro using a microtiter 363 
plate assay as previously described (28). Briefly, sterile 96-well microtiter plates were coated 364 
with 100 μl of 20% carbonate/bicarbonate–reconstituted human plasma (Sigma) and incubated 365 
overnight at 4oC. Bacterial cultures were grown overnight in TSB supplemented with 3% sodium 366 
chloride and 0.5% glucose (biofilm medium, BFM) at 37°C. Cultures were standardized to an 367 
OD560 = 0.05 in fresh BFM. Plasma was gently aspirated, and the microtiter plate inoculated with 368 









200 μl of standardized culture per well. The plate was incubated statically overnight at 37°C. 369 
Wells were gently washed three times with 200 μl PBS, fixed with 200 μl 100% EtOH, stained 370 
with 200 μl Gram’s crystal violet, and finally washed three times with 250 μl PBS. The stain was 371 
eluted with 100 μl 100% EtOH for 10 min, the eluent diluted into a new 96-well plate, and the 372 
absorbance was measured at 595 nm with a FLUOstar Omega microplate reader (BMG 373 
Labtech). 374 
Total protease activity. Total protease activity of CM was assessed using the FRET-375 
based Protease Fluorescent Detection Kit (Sigma) and the EnzChek® Gelatinase/Collagenase 376 
Assay Kit (ThermoFisher Scientific), both according to the manufacturer instructions.  377 
Protease reporter assay. Stains carrying each protease reporter (pCM13, pCM15, 378 
pCM16, or pCM35) were cultured in TSB overnight as detailed above. Cultures were then 379 
standardized to an OD560 of 10.0. 200 μl of each standardized culture was then aliquoted in 380 
triplicate into a black clear-bottomed 96-well plate and the mean fluorescence intensity (MFI) 381 
measured with a FLUOstar Omega microplate reader (excitation: 485 nm, emission: 520 nm) 382 
(BMG Labtech).  383 
PIA immunoblot. Production of the polysaccharide intercellular adhesion (PIA) was 384 
assessed as previously described with minor modifications (44). Specifically, cultures were 385 
grown overnight in BFM. After standardization to OD560 of 5.0, cells were harvested by 386 
centrifugation and re-suspended in 60 μl 0.5 M EDTA. Cell suspensions were boiled for 5 min 387 
followed by centrifugation (14,000 x g for 2 min). 40 μl of the supernatant was then incubated for 388 
30 min at 48oC with 1 μl proteinase K (10 mg/ml) at 48°C. 20 μl of Tris-buffered saline (20 mM 389 
Tris-HCl, 150 mM NaCl [pH 7.4]) was added to each sample, which was then stored at −20°C. 390 
For analysis, 2 μl of each sample was spotted directly to a dry nitrocellulose membrane and PIA 391 
detected using an anti-PIA antibody as previously described (44). 392 
Characterization of exoprotein profiles. Exoprotein profiles were examined as previously 393 
described (1). CM harvested as described above was resolved by SDS-PAGE using 4-12% 394 









gradient Novex Bis-Tris Plus gels (Life Technologies). Proteins were visualized by staining with 395 
SimplyBlueTM SafeStain (Life Technologies). Images were obtained using a Bio-Rad 396 
ChemiDocMP Imaging System (Bio-Rad Laboratories).  397 
Staphyloxanthin production. The relative production of staphyloxanthin was assessed 398 
using bacterial cells harvested from overnight cultures as previously described (27). Briefly, cells 399 
were harvested and standardized to an OD560 = 10.0 and washed twice with sterile water. Cells 400 
were then re-suspended in 1.0 ml of 100% methanol and heated at 55°C for 5 min with 401 
occasional vortexing. The cells were removed by centrifugation at 15,000 × g for 1 min and 100 402 
μl of supernatant into a 96-well microtiter plate in triplicate. Absorbance values were read on a 403 
FLUOstar Omega microplate reader (BMG Labtech) at a 465 nm and background corrected with 404 
a methanol blank. 405 
Murine model of post-traumatic osteomyelitis. The murine model of acute posttraumatic 406 
osteomyelitis model was performed as previously described (43). Prior to surgery, 8-10 week 407 
old C57BL/6 mice received 2.0 mg/kg of body weight meloxicam via subcutaneous injection and 408 
were then anesthetized with isoflurane for the duration of the surgery. For each mouse, an 409 
incision was made above the right hind limb. The periosteum was pulled apart with forceps and 410 
using a 21-gauge Precision Glide needle (Becton Dickinson), a 1-mm uni-cortical bone defect 411 
was made at the lateral mid-shaft of the femur. A bacterial inoculum of 1 × 106 CFU in 2 μl of 412 
PBS was delivered into the intramedullary canal. The periosteum and skin were then closed 413 
with sutures, and the mice were allowed to recover from anesthesia. Infection was allowed to 414 
proceed for 14 days thereafter, at which time the mice were euthanized and the right femur was 415 
removed and subjected to micro-computed tomography (micro-CT) analysis. All experiments 416 
involving animals were reviewed and approved by the Institutional Animal Care and Use 417 
Committee of the University of Arkansas for Medical Sciences and were performed according to 418 
NIH guidelines, the Animal Welfare Act, and U.S. federal law. 419 









Micro-computed tomography. The analysis of cortical bone destruction and new bone 420 
formation was performed using micro-CT imaging with a Skyscan 1174 micro-CT (Bruker), and 421 
scans were analyzed using the manufacturer's analytical software. Briefly, axial images of each 422 
femur were acquired at a resolution of 6.7 μm at 50 kV and 800 μA through a 0.25-mm 423 
aluminum filter. Bones were visualized using a scout scan and then scanned in three sections 424 
as an oversize scan to image the entire femoral length. The volume of cortical bone was 425 
isolated in a semi-automated process per the manufacturer's instruction. Briefly, cortical bone 426 
was isolated from soft tissue and the background by global thresholding (low threshold, 89; high 427 
threshold, 255). The processes of opening, closing, dilation, erosion, and de-speckling were 428 
configured using the bones from sham-treated controls to separate the new bone from the 429 
existing cortical bone, and a task list was created to apply the same process and values to all 430 
bones in the data set. After processing of the bones using the task list, the volume of interest 431 
(VOI) was corrected by drawing inclusive or exclusive contours on the periosteal surface. 432 
Cortical bone destruction analysis consisted of approximately 1,800 slices between anatomical 433 
landmarks at opposing ends of the femur. Destruction was determined by subtraction of the 434 
volume of infected bones from the average bone volume from sham-treated controls. Reactive 435 
new bone formation was assessed by first isolating the region of interest (ROI) that contained 436 
only the original cortical bone (as described above). After cortical bone isolation, the new bone 437 
volume was determined by subtraction of the cortical bone volume from the total bone volume. 438 
All calculations were performed on the basis of direct voxel counts. 439 
Statistical analysis. To allow for statistical comparison across biological and experimental 440 
replicates, the results obtained for each experimental replicate with each strain were averaged 441 
across all biological replicates. For densitometric analyses of western blots, protease assays, 442 
biofilm assays and pigmentation assays, results observed with the isogenic wild-type strain 443 
were set to 1.0, and these averages were then plotted relative to the results observed with this 444 
strain. For protease reporter assays and µCT analysis, absolute values were plotted for all 445 









replicates obtained with each strain. Analysis of variance (ANOVA) models with Dunnett’s post-446 
test adjustment was used to assess statistical significance. P-values ≤ 0.05 were considered to 447 
be statistically significant. Statistical analyses were performed using the statistical programming 448 
language R version 3.3.3 (Vienna, Austria), SAS 9.4 (Cary, NC) and GraphPad Prism 5.0 (La 449 
Jolla, CA). 450 
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FIGURE LEGENDS 638 
Fig. 1. Impact of msa on the accumulation of SarA. SarA accumulation was 639 
assessed by western blot of whole cell lysates prepared from mid-, late- or post-640 
exponential phase cultures of LAC, UAMS-1 (U1), and their isogenic msa and sarA 641 
mutants. Bar charts illustrate densitometry based on two biological replicates. 642 
Densitometry results from samples prepared from each parent strain using cells 643 
obtained at each growth phase were standardized to OD
560
 = 10. Error bars indicate 644 
standard error of the mean. Single asterisk indicates statistical significance relative to 645 









the isogenic parent strain. Double asterisks indicate statistical significance relative to 646 
the isogenic sarA mutant.  647 
 648 
Fig. 2. Impact of msa and sarA on biofilm formation. Biofilm formation was assessed 649 
with the LAC, UAMS-1, their sarA and msa mutants, as well as mutants complemented 650 
with sarA (S) or msa (M). Bar chart represents cumulative results from at least two 651 
biological replicates, each of which included five experimental replicates. Error bars 652 
indicate standard error of the mean. Single asterisk indicates statistical significance 653 
relative to the isogenic parent strain. Double asterisks indicate statistical significance 654 
relative to the isogenic sarA mutant.  655 
 656 
Fig. 3. SarA accumulation in sarA- and msa-complemented mutants. SarA 657 
accumulation was assessed by western blot of whole cell lysates prepared from mid-658 
exponential phase cultures of LAC, UAMS-1, their sarA and msa mutants, as well as 659 
mutants complemented with sarA (S) or msa (M). Bar charts illustrate densitometry 660 
based on at least two experimental replicates. Densitometry was performed using 661 
samples prepared from cells obtained at mid-exponential growth phase (standardized to 662 
OD560 = 1.5). Error bars indicate standard error of the mean. Single asterisk indicates 663 
statistical significance relative to the isogenic parent strain. Double asterisks indicate 664 
statistical significance relative to the isogenic sarA mutant. 665 
 666 
Fig. 4. Impact of msa and sarA on protease production. Protease activity in 667 
conditioned medium (CM) was assessed with LAC, UAMS-1, their sarA and msa 668 
mutants, as well as mutants complemented with sarA (S) or msa (M). Protease activity 669 









was assessed using a FITC-casein cleavage hydrolysis assay (left) and an FITC-gelatin 670 
cleavage hydrolysis assay (right). Results are reported as mean fluorescence values 671 
(MFI) ± the standard error of the mean. Bar charts are representative of results from at 672 
least two biological replicates, each of which included three experimental replicates. 673 
Error bars indicate standard error of the mean. Single asterisk indicates statistical 674 
significance relative to the isogenic parent strain. Double asterisks indicate statistical 675 
significance relative to the isogenic sarA mutant.  676 
 677 
Fig. 5. Impact of msa and sarA on protease gene expression. Reporter constructs 678 
were generated using the promoters from each of the four genes/operons encoding 679 
extracellular proteases and the gene encoding green fluorescent protein (gfp). Each 680 
construct was introduced into LAC, UAMS-1, and their isogenic sarA and msa mutants. 681 
Mean fluorescence intensity (MFI) was assessed after overnight cultures were 682 
standardized to an OD
560
 = 10. Bars represent average MFI ± standard error of the 683 
mean from each of two independent biological replicates, each of which included three 684 
experimental replicates. Statistical analysis was done independently for each strain and 685 
each reporter. Single asterisk indicates statistical significance compared to the isogenic 686 
parent strain. Double asterisk indicate statistical significance compared to the isogenic 687 
sarA mutant.  688 
 689 
Fig. 6. Impact of extracellular proteases on accumulation of specific proteins. The 690 
abundance of alpha toxin (Hla) and extracellular protein A (eSpa) was assessed by 691 
western blot of CM obtained from stationary phase cultures of LAC and UAMS-1, their 692 
sarA and msa mutants, and isogenic derivatives of each strain unable to produce 693 









extracellular proteases (prot). Purified Spa and Hla was included as positive controls. 694 
CM from LAC spa and hla mutants were included as negative controls. 695 
 696 
Fig. 7. Impact of sarA and msa on accumulation of extracellular proteins. 697 
Extracellular protein profiles were assessed by SDS-PAGE analysis of CM obtained 698 
from stationary phase cultures of LAC, UAMS-1, their sarA and msa mutants, and 699 
isogenic derivatives of each strain unable to produce extracellular proteases (prot).  700 
 701 
Fig. 8. Impact of proteases on Nuc1 production and processing in sarA and msa 702 
mutants. The amount of extracellular nuclease was assessed by western blot using CM 703 
from LAC, UAMS-1, their isogenic sarA and msa mutants, sarA (S) or msa (M) 704 
complemented variants, and isogenic derivatives of regulatory mutants unable to 705 
produce extracellular proteases (prot). A UAMS-1 nuc1 (nuc) mutant was included as a 706 
negative control in both blots. 707 
 708 
Fig. 9. Impact of extracellular proteases and nucleases on biofilm formation in 709 
msa and sarA mutants. Biofilm formation was assessed with LAC, UAMS-1, their sarA 710 
and msa mutants, and isogenic derivatives of each strain unable to produce either 711 
extracellular proteases (prot, top) or the extracellular nuclease Nuc1 (nuc, bottom). Bar 712 
chart indicates cumulative results from at least two biological replicates, each of which 713 
included five experimental replicates. Error bars indicate standard error of the mean. 714 
Single asterisk indicates statistical significance relative to the isogenic parent strain. 715 
Double asterisks indicate statistical significance relative to the isogenic sarA mutant. 716 
Triple asterisks indicate statistical significance relative to the isogenic msa mutant.  717 










Fig. 10. Staphyloxanthin production in sarA and msa mutants. Pigment was 719 
extracted from standardized samples of bacteria grown to stationary phase and 720 
measured at an absorbance of 465 nm. Bar charts represent cumulative results from at 721 
least four biological replicates, each of which included three experimental replicates. 722 
Error bars indicate standard error of the mean. Single asterisk indicates statistical 723 
significance relative to the isogenic parent strain. Double asterisks indicate values that 724 
are statistically significant relative to the isogenic sarA mutants. 725 
 726 
Fig. 11. Impact of sarA and msa on the virulence of LAC and UAMS-1 in an 727 
osteomyelitis model. Images were analyzed for cortical bone destruction and reactive 728 
(new) bone formation in C57BL/6 mice infected with LAC, UAMS-1, or their isogenic 729 
sarA and msa mutants. Values are presented as volumes relative to mock-infected mice 730 
which underwent the surgical procedure but were injected only with sterile PBS. At least 731 
ten mice were analyzed for each mutant or respective parent strain. Single asterisk 732 
indicates statistical significance relative to the isogenic parent strain. Double asterisks 733 
indicate statistical significance relative to the isogenic sarA mutant. 734 
 735 
TABLE 1. sarA expression at mid-exponential growth phase 736 
Strain Expression compared to WT 
LAC ΔmsaABCR 0.493   0.01 
LAC ΔmsaABCR, pCN34::msaABCR 0.984   0.0168 
UAMS-1 ΔmsaABCR 0.753  0.016 
UAMS-1 ΔmsaABCR, pCN34::msaABCR 0.875  0.019 
 737 
TABLE 2. LAC S. aureus strains used in this study. 738 









  739 
a
 Variant of the clinical isolate LAC which has been cured of the erythromycin resistance 740 
plasmid as previously described (1). 741 
 742 
Table 3. UAMS-1 S. aureus strains used in this study. 743 
Strain Genotype References 
UAMS-2279a Wild type 1 
UAMS-2294 sarA::kan/neo 1 
UAMS-4001 sarA::kan/neo, pSARA 1 
UAMS-4520 ΔmsaABCR 27 
UAMS-4521 ΔmsaABCR, pCN34::msaABCR 27 
UAMS-4601 ΔmsaABCR, pSARA This work 
UAMS-4545 ΔmsaABCR, sarA::kan/neo This work 
UAMS-4222 Wild type, pCM13 (aur::sgfp) 23 
UAMS-4223 sarA::kan/neo, pCM13 (aur::sgfp) This work 
UAMS-4537 ΔmsaABCR, pCM13 (aur::sgfp) This work 
UAMS-4226 Wild type, pCM15 (spl::sgfp) 23 
UAMS-4227 sarA::kan/neo, pCM15 (spl::sgfp) This work 
UAMS-4538 ΔmsaABCR, pCM15 (spl::sgfp) This work 
UAMS-4230 Wild type, pCM16 (ssp::sgfp) 23 
UAMS-4231 sarA::kan/neo, pCM16 (ssp::sgfp) This work 
UAMS-4539 ΔmsaABCR, pCM16 (ssp::sgfp) This work 
UAMS-4234 Wild type, pCM35 (scp::sgfp) 23 
UAMS-4235 sarA::kan/neo, pCM35 (scp::sgfp) This work 
UAMS-4446 spa::erm 34 
UAMS-4552 hla::erm 52 
UAMS-4540 ΔmsaABCR, pCM35 (scp::sgfp) This work 
UAMS-3001 Δaur, ΔsspAB, ΔscpA, spl::erm 47 
UAMS-3002 sarA::kan/neo, Δaur, ΔsspAB, ΔscpA, spl::erm 1 
UAMS-4557 ΔmsaABCR; Δaur, ΔsspAB, ΔscpA, spl::erm This work 
UAMS-2280 nuc::ltrB 41 
UAMS-2295 sarA::kan/neo, nuc::ltrB This work 
UAMS-4582 ΔmsaABCR, nuc::ltrB This work 
Strain Genotype References 









  744 
UAMS-1 Wild type 48 
UAMS-929 sarA::kan/neo 30 
UAMS-969 sarA::kan/neo, pSARA::cat 30 
UAMS-4499 ΔmsaABCR 46 
UAMS-4500 ΔmsaABCR, pCN34::msaABCR 46 
UAMS-4603 ΔmsaABCR, pSARA This work 
UAMS-4549 ΔmsaABCR; sarA::kan/neo  This work 
UAMS-4220 Wild type, pCM13 (aur::sgfp) This work 
UAMS-4221 sarA::kan/neo, pCM13 (aur::sgfp) This work 
UAMS-4541 ΔmsaABCR, pCM13 (aur::sgfp) This work 
UAMS-4224 Wild type, pCM15 (spl::sgfp) This work 
UAMS-4225 sarA::kan/neo, pCM15 (spl::sgfp) This work 
UAMS-4542 ΔmsaABCR, pCM15 (spl::sgfp) This work 
UAMS-4228 Wild type, pCM16 (ssp::sgfp) This work 
UAMS-4229 sarA::kan/neo, pCM16 (ssp::sgfp) This work 
UAMS-4543 ΔmsaABCR, pCM16 (ssp::sgfp) This work 
UAMS-4232 Wild type, pCM35 (scp::sgfp) This work 
UAMS-4233 sarA::kan/neo, pCM35 (scp::sgfp) This work 
UAMS-4544 ΔmsaABCR, pCM35 (scp::sgfp) This work 
UAMS-321 ica::tet 49 
UAMS-1624 codY::ermC 50 
UAMS-4412 xerC::erm 51 
UAMS-1471 Δnuc 13 
UAMS-1477 sarA::kan/neo, Δnuc 13 
UAMS-4556 ΔmsaABCR, Δnuc This work 
UAMS-4574 Δaur, ΔsspAB, scpA::tet This work 
UAMS-4578 sarA::kan/neo, Δaur, ΔsspAB, scpA::tet This work 
UAMS-4583 ΔmsaABCR, Δaur, ΔsspAB, scpA::tet This work 
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